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Introduction: Most patients with asthma and many patients with COPD show bronchial
hyperresponsiveness to adenosine (BHRAMP). BHRAMP may be caused by release of mast cell
histamine, which induces smooth muscle contraction.
Aim of the study: To evaluate whether mast cell numbers in airway smooth muscle are
increased in patients with asthma and COPD compared to their age-matched controls, and
whether mast cell numbers are correlated with BHRAMP.
Patients: Twenty-two non-smoking subjects with asthma (age 31 yr, FEV1: 89% pred,
PC20AMP: 2.7mg/ml), 18 ex-smoking subjects with COPD (age 62 yr, FEV1: 58% pred,
PC20AMP: 52.4mg/ml).
Methods: Snap-frozen bronchial biopsies were immunostained with anti-mast cell
tryptase and anti-desmin antibodies. Mast cell number was expressed as the number of
tryptase positive cells per area of smooth muscle.
Results: There were no significant differences in mast cell number between patients with
asthma, COPD, and their respective age-matched healthy controls. Furthermore, there
was no significant correlation between mast cell number and FEV1 or PC20AMP in any of the
groups. Surprisingly, the mast cell number was negatively correlated with reversibility to
salbutamol in COPD patients (rho 0.47, Po0:05).
Conclusion: Mast cell numbers in central airway smooth muscle apparently do not
contribute importantly to bronchial hyperresponsiveness to adenosine.
& 2006 Elsevier Ltd. All rights reserved.Elsevier Ltd. All rights reserved.
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int.umcg.nlIntroduction
Most patients with asthma and many smoking patients with
COPD show increased bronchial hyperresponsiveness to
adenosine (BHRAMP).
1,2 The underlying mechanism of this
BHRAMP is not completely understood, partially because
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available in humans so far. Probably, adenosine acts
indirectly through activation of specific (A2) receptors on
intermediate inflammatory cells such as mast cells and on
afferent nerve endings.3
A role of mast cells in the responsiveness to adenosine is
supported by the observation that plasma histamine
increases in atopic non-asthmatics after a challenge with
AMP,4 next to histamine, prostaglandin D2 and tryptase
increases in bronchoalveolar lavage fluid.5
Because BHRAMP may well depend on the number and
activation state of bronchial mast cells, this test might be a
useful marker of allergic airway inflammation in clinical
practice.6 Indeed, atopic subjects respond relatively more
to inhaled adenosine than to methacholine as compared to
non-atopic controls.4 Also, the early asthmatic reaction
after house dust mite is better reflected by an increase in
hyperresponsiveness to AMP than to methacholine.7,8 Non-
atopic patients with COPD who currently smoke show also
more severe hyperresponsiveness to AMP than ex-smokers.9
Because the number of mast cells is larger in the
peripheral10 as well as the central airways11 of smokers
than of non-smokers, mast cells may also play a role in the
increased hyperresponsiveness to AMP in smoking-related
airway diseases.
Based on the above one would expect a close relationship
between the severity of BHRAMP and mast cell number in
bronchial biopsies from allergic patients with asthma and
smokers with COPD. However, we could not demonstrate
such a relationship in stable patients with asthma, nor in
COPD.12,13 One explanation for this discrepancy may be that
the number of mast cells was measured in the bronchial
mucosa, and not in the smooth muscle area of the bronchus.
After all, in vitro sensitisation with common aeroallergens
increases mast cell numbers specifically within the smooth
muscle area of human bronchi, in contrast to mast cells in
the epithelium, lamina propia or adventitia.14 In addition,
airway smooth muscle- and mast cells may interact closely
as smooth muscle cells secrete stem cell factor which
activates mast cells and prolong their survival.15 Moreover,
mast cells secrete tryptase which may stimulate smooth
muscles to produce TGF-b1.16,17 This chemokine and also
RANTES18 have chemotactic activity to mast cells.
Therefore, we set out to investigate whether the numbers
of smooth muscle mast cells are higher in patients with
asthma and COPD than in their respective non-hyperrespon-
sive controls and if these numbers are related to the severity
of BHRAMP.Materials and methods
Subjects
Bronchial biopsies were obtained from two previously
published studies.12,13 Subjects participating in these 2
studies were recruited from the pulmonary outpatient clinic
of the University Medical Center Groningen and by adver-
tisements in local newspapers. All subjects gave written
informed consent. The medical ethics committee of the
University Medical Center Groningen approved this investi-
gation.Asthmatic subjects aged between 18 and 45 years were
selected based on a history consistent with asthma: a
positive history of atopy, i.e. positive intracutaneous tests
against house dust mite or two other common aero-allergens
(ALK, Groningen, The Netherlands), FEV141.5 l and460%
predicted, PC20 methacholinebromide p9.8mg/ml and PC
20 AMP p80mg/ml. Age matched healthy volunteers were
selected on: no history of lung disease, FEV141.5 l and485%
predicted, no atopy and no airways responsiveness to
methacholine or AMP.
COPD subjects aged between 45 and 75 years were
selected based on criteria of the American Thoracic Society
(ATS); a negative history of atopy, negative skin test to 18
common aero-allergens (ALK, Groningen, The Netherlands),
i.e. negative specific serum IgE for 11 common aero-
allergens (phadiatops). Healthy volunteers did not have a
history of pulmonary disease, had a normal lung function,
and were matched for age and packyears smoking.
Any subject who smoked during the past year, suffered
from a respiratory infection during the past 4 weeks, or was
treated with oral or inhaled corticosteroids or antibiotics
during the past 4 weeks was excluded.
Lung function measurements
Forced expiratory volume in one second (FEV1) was
performed according to the standardized guidelines of the
European Respiratory Society.19 Reversibility was tested
30min after inhalation with 400 mg salbutamol. Subjects
were not allowed to use short-acting bronchodilators within
12 h, or long-acting bronchodilators within 24 h.
Bronchial provocation test to AMP
Provocation tests were performed using a 2min tidal
breathing method.20 After an initial nebulized saline
challenge, subjects inhaled doubling concentrations AMP,
ranging from 0.04 to 80 (asthma) or 320mg/ml (COPD)
(Sigma, St Louis, USA) till FEV1 declined 20% compared to
the baseline value. The arbitrary cut-off point for healthy
subjects was set at 80mg/ml AMP (asthma controls) and
320mg/ml AMP (COPD controls).
Bronchoscopy and processing of the biopsies
Bronchoscopy was performed using an Olympus B1 IT10
flexible fiberoptic bronchoscope (Olympus Optical, Tokyo,
Japan), according to the guidelines of the ATS.21 Biopsies were
taken from the subcarinae of the left or right lower lobe using
a fenestrated forceps (FB-21C, Olympus, Tokyo, Japan). At
least five biopsies per patient were collected. Biopsies were
mounted in Tissue Teks (optimal cutting temperature
medium) embedding compound and snap-frozen by immersing
in isopentane (80 1C). Every biopsy was stained with
haematoxylin and eosin and qualitatively examined for the
amount of smooth muscle present. Sections without smooth
muscle were excluded. Frozen sections of 4mm thickness were
double immuno-stained with anti-mast cell tryptase (AA1 from
DAKO, ITK, Denmark) and anti-desmin antibodies (anti-Desmin
from DAKO, Glostrup, Denmark, Fig. 1). Anti-mast cell
antibodies were labelled with alkaline phosphatase (resulting
in blue colour precipitate), and the anti-desmin antibodies
with peroxidase/AEC (red colour precipitate). The observer
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sections. Counting was carried out using a light microscope
at a magnification of 200 . Tryptase positive cells were
counted in 2 random, but representative sections of one
biopsy per patient with at least an 80mm interval. Counting
was started at those locations that met best the above-
mentioned criteria. The area of smooth muscle was deter-
mined by grid counting using an eyepiece graticule (cross-
points each 100mm at 100 ). In this way, we evaluated per
subject a mean (SD) area of 0.59 (0.40)mm2. Mast cell number
was expressed as the number of tryptase positive cells per
area smooth muscle.Data analysis
All analyses were performed with the SPSS 10 software
package (SPSS Inc., Chicago, IL). Values of Po0:05 wereTable 1 Clinical characteristics and mast cell density.
Asthma Cont
Male/female 13/9 4/5
Age, years 31.3 (8.9) 32.3
Pack years 0 0
Current smoking 0 0
Atopy + 
FEV1, % predicted 89.2 (15.8) 106 (
Reversibility, % predicted FEV1 10.5 (9.9)
 2.0 (
PC20AMP, mg/ml 2.7 (0.18–22.8)
 480
Tryptase+ cell number/mm2 96.6 (13–222) 127 (
Baseline characteristics presented as mean (SD). PC20AMP presented a
as median (range).
Po0.05 vs. COPD.
Figure 1 Photograph of a snap-frozen bronchial biopsy of a
patient with asthma. The section was double immuno-stained
with anti-mast cell tryptase (alkaline phosphatase, blue
precipitate) and anti-desmin (peroxidase/AEC, red precipitate).
The area of smooth muscle was determined by gridcounting.considered statistically significant. The Student’s t-test was
used to compare clinical variables between groups, on
condition of a normal distribution. The Mann–Whitney U test
was used to compare mast cell density between groups.
Correlations between mast cell density and clinical variables
were made using Spearman’s rank correlation tests.
Results
Clinical characteristics
Twenty-two patients with asthma, 18 patients with COPD,
and 2 control groups of 9 healthy subjects participated in
this study (Table 1). The 37 male and 21 female subjects
were equally distributed between the four groups
(P ¼ 0:19). Mean reversibility of the FEV1% predicted after
400 mg salbutamol of the asthmatic subjects was significantly
larger than that of healthy controls (10.5 vs. 2.0%), whereas
reversibility of patients with COPD and their healthy
controls was similar (5.6 vs. 3.3, respectively). Geometric
mean PC20AMP of the COPD patients was 52.4mg/ml (range
1 to 4320) 9 individuals had a PC20AMP o320mg/ml.
Geometric mean PC20AMP of the asthmatic patients was
2.7mg/ml (range 0.18–22.8). None of the participants used
mast cell stabilizers, H1 blockers, 5-lipoxygenase inhibitors,
theophyllines, or any other agents that may have influenced
mast cells.
Differences in mast cell density in airway smooth
muscle
There were no significant differences between asthmatics,
patients with COPD and their controls, or between the two
healthy control groups (see Table 1).
Correlations between mast cell density and clinical
variables
In the group of 18 COPD patients, the correlation (rho)
between mast cell density and FEV1% predicted, reversibility
% predicted FEV1 and PC20AMP is 0.42 (not significant),rols for asthma COPD Controls for COPD
13/5 7/2
(9.3) 62.4 (8.0) 58.7 (8.2)
25 (0-69) 25 (10-55)
0 0
 
13.9) 58.1 (13.7) 105 (11.1)
1.9) 5.6 (2.5) 3.3 (3.2)
52.4 (1–4320) 4320
30–262) 122 (19–423) 130 (33–298)
s geometric mean (range). Tryptase+ cell number/mm2 presented
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Figure 2 Significant correlation between the density of
tryptase positive cells (mast cells) in the smooth muscle area
(per mm2) of bronchial biopsies and the degree of reversibility
of FEV1% predicted in 18 subjects with stable COPD.
Mast cells in airway smooth muscle 8850.47 (Po0:05) (see Fig. 2), and 0.35 (not significant),
respectively.
In the group of 22 asthmatic patients, the correlation
(rho) between mast cell density and FEV1% predicted,
reversibility % predicted FEV1, and PC20AMP is 0.17, 0.24,
and 0.28, respectively (all not significant).
Subgroup analyses
Retrospectively we analysed the subgroup (n ¼ 9) of AMP
positive COPD patients. No significant differences between
COPD and their healthy controls were found regarding mast
cell density in airway smooth muscle. Also, no significant
correlation was found between mast cell density and
PC20AMP.
Discussion
Increased bronchial hyperresponsiveness to AMP can be
demonstrated in all asthmatics and many patients with
COPD. Increased BHRAMP may be caused by a release of mast
cell histamine, which induces smooth muscle contraction.
Therefore, it was expected to find a close relationship
between mast cell density in airway wall biopsies in the
epithelial and subepitelial layer and PC20AMP. In former
studies no such relationship was found, neither in patients
with asthma nor in patients with COPD. Therefore, we
speculated that we might have to look more specifically to
mast cells in the smooth muscle area of bronchial biopsies.
Nevertheless, in the present study mast cell density in
smooth muscle area was not increased in asthma and COPD
compared to age matched controls, and mast cell density
did not correlate with BHRAMP. Interestingly, we demon-
strated a negative correlation between mast cell density
and reversibility of airway obstruction to salbutamol in
COPD patients, despite the low level of reversibility present.
We do not have a good explanation for the latter finding.
There are several explanations why mast cell numbers in
airway smooth muscle are not increased in our patients with
asthma or COPD, and why this is not related to severity ofbronchial hyperresponsiveness to AMP. First, mast cell
numbers increase upon allergen exposure22 and smok-
ing.11,23 Our patients were very stable and not recently
exposed to allergens or cigarette smoke. It may thus well be
that the mast cells in the bronchial wall were not increased
in number nor activated. Second, we took bronchial biopsies
from the central, but not peripheral airways. It is possible
that peripheral mast cell activation is more important than
central mast cell activation with respect to increased
hyperresponsiveness to AMP, since it has been shown that
mast cell mediators (histamine, prostagandin D2, tryptase)
are increased in (peripherally collected) BAL fluid after
challenge with AMP.5 In line with this Carroll et al. showed in
patients with fatal and non-fatal asthma that the density of
mast cells in the complete bronchial wall, but also in airway
smooth muscle, is much higher in the peripheral airways
than in the central airways. Moreover, a significant part of
these mast cells (66–75%) was found to be degranulated.24
Third, we took bronchial biopsies that represent only small
and superficial parts of the bronchial wall. In contrast, the
complete smooth muscle area of bronchial sections was
examined in the study of Ammit et al.14 who showed
increased numbers of mast cells in sensitised smooth
muscle. Fourth, we applied specific immunostaining techni-
ques directed at tryptase (AA1), using the light microscope
to evaluate the number of tryptase positive cells. Although
less likely in our stable study subjects, it cannot completely
be ruled out that mast cells may have degranulated to a
certain extent; these degranulated cells may not be
visualized and this could contribute to underestimation of
the real number of mast cells and their activation status.25
Finally, there is evidence that other pathways than via the
A2B-receptor on mast cells, namely involving the A1-
receptor, may be responsible for the AMP-induced bronch-
oconstriction.26,27 Although the A1-receptor is not abun-
dantly present in the human lung tissue in binding studies, it
is associated with nerves and functional studies suggest a
possible neural pathway.28,29 Furthermore, it has been
shown that activation of adenosine A1 receptors directly
stimulates contraction of human bronchial smooth muscle
cells by activation of Ca2+-channels.30
One other study investigating the same research question
had different results.31 This study demonstrated signifi-
cantly more mast cells in airway smooth muscle of
asthmatics than in healthy controls. Furthermore, a positive
correlation was found between mast cell numbers in smooth
muscle areas and bronchial hyperresponsiveness to metha-
choline in asthmatics. There are some differences between
their and our study. First their asthmatics were on average
10 years younger and some of their asthmatics were non-
atopic. They used a (semi)automatic computerized method
while we counted manually. Finally they used methacholine
to stimulate airway smooth muscle; a challenge not acting
via mast cells. In contrast in our study AMP was used to
stimulate airway smooth muscle cells indirectly by releasing
histamine from immunologically primed mast cells. There-
fore, it is intriguing that they found a positive correlation
between mast cell density and hyperresponsiveness, while
we did not. Obviously more studies are needed using both
AMP and methacholine to determine the relationship
between bronchial hyperresponsiveness and mast cell
infiltration in airway smooth muscle.
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between airway mast cell density in the smooth muscle area
and reversibility of airway obstruction in COPD patients
(rho ¼ 0.47, P ¼ 0:048), which was not present in asthma.
Interestingly, Grashoff and coworkers23 demonstrated a very
similar correlation between mast cell density and reversi-
bility of airway obstruction (rho ¼ 0.42, P ¼ 0:03) in
smoking and non-smoking individuals with and without
COPD. They used resected lung specimens, demonstrating
the above-described relationship in the non-epithelial part
of the small airways. There are a few hypothetical
explanations why an increased airway mast cell density
may be related to a loss of airway reversibility with
salbutamol. Mediators of airway inflammatory cells, includ-
ing mast cells, may impair the function of b2-receptors.
32,33
However, one would also expect to find a relationship
between increased mast cell density and increased BHRAMP,
if an increased bronchomotor tone due to desensitised b2-
receptor function plays a role. Furthermore, mediators of
inflammatory cells in the airway wall may lead to a
decreased distensibility, which may be an expression of
airway remodelling. Indeed mast cells have been suggested
to contribute importantly to the development of airway
fibrosis via proteolytic activation cascades and/or the
release of heparin and subsequent effects on growth factor
activity, but future studies have to confirm this.34
We conclude that mast cell numbers in airway smooth
muscle in central airways do not contribute importantly to
bronchial hyperresponsiveness to adenosine neither in
asthma nor in ex-smokers with COPD.
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